SAN DIEGO--(BUSINESS WIRE)--Mentor Capital, Inc. (PINK SHEETS:MNTR) announced today that it has added Provectus Pharmaceuticals, Inc. (PVCT:OB) to Mentor Capital’s proprietary Cancer Immunotherapy Index effective as of February 22, 2010. To add Provectus to the CI Index, Mentor Capital has recently taken a significant initial position in Provectus through Mentor Capital’s managed fund. Mentor notes that Provectus has advanced 23% during this first trading week on the Index and those results are reported on the current CI Index update.
